|
|
Volumn 103, Issue 5, 2011, Pages 366-367
|
|
NSCLC drug targets acquire new visibility.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE;
ANTINEOPLASTIC AGENT;
BENZENESULFONIC ACID DERIVATIVE;
BENZIMIDAZOLE DERIVATIVE;
BEXAROTENE;
EML4 ALK FUSION PROTEIN, HUMAN;
EML4-ALK FUSION PROTEIN, HUMAN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
GEFITINIB;
N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE;
N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE;
ONCOPROTEIN;
PF-02341066;
PIPERIDINE DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
PYRAZOLE DERIVATIVE;
PYRIDINE DERIVATIVE;
QUINAZOLINE DERIVATIVE;
SELUMETINIB;
SORAFENIB;
TETRALIN DERIVATIVE;
TUMOR MARKER;
DRUG ANTAGONISM;
DRUG EFFECT;
GENETICS;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
METABOLISM;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
MUTATION;
NOTE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
BENZENESULFONATES;
BENZIMIDAZOLES;
CARCINOMA, NON-SMALL-CELL LUNG;
HUMANS;
LUNG NEOPLASMS;
MOLECULAR TARGETED THERAPY;
MUTATION;
ONCOGENE PROTEINS, FUSION;
PIPERIDINES;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
PYRAZOLES;
PYRIDINES;
QUINAZOLINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
TETRAHYDRONAPHTHALENES;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 79954453453
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr056 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
